Pharmaceuticals
PAG acquires Indian CDMO Acme for $145m
PAG has acquired a controlling stake in Acme Formulation Private, an India-based contract development and manufacturing organization (CDMO), for approximately $145 million.
Hong Kong sees rush of VC-backed biotech IPO filings
Five VC-backed pre-revenue Chinese biotech companies have filed to list in Hong Kong over the past two weeks, doubling the size of the IPO pipeline in this category.
Sherpa Healthcare leads Series A for Paq Therapeutics
Sherpa Healthcare Partners has led a $30 million Series A for Paq Therapeutics, a Chinese-founded biotech company specializing in treatments based on molecules that enhance the degradation of disease-causing entities.
China drug developer Adlai Nortye gets $100m Series D
Adlai Nortye, a Chinese biopharma player specializing in cancer treatments, has raised $100 million in Series D funding.
China CRO player raises $50m to support US merger
DMed-Clinipace, a global contract research organization (CRO) with a presence in China, has raised $50 million in an extended Series C round led by Springhill Fund. Rock Springs Capital and Superstring Capital also took part.
China's Qiming targets listed healthcare businesses
Qiming Venture Partners is mobilizing its newly launched public equities unit – and $500 million fund – to participate as an anchor investor in Hong Kong IPOs by Chinese healthcare companies.
HutchMed soars on debut after $536m Hong Kong offering
HutchMed – formerly Hutchison China MediTech – saw its share price jump 50% on debut after raising HK$4.17 billion ($536.9 million) through a Hong Kong share offering.
Warburg Pincus leads Series C for China AI drug developer
Insilico Medicine, which leverages artificial intelligence (AI) technology to speed up the drug development process, has closed a $255 million Series C funding round led by Warburg Pincus.
Chinese drug developer Abbisko files for HK IPO
PE-backed Abbisko Therapeutics, which focuses on the discovery and development of innovative and differentiated small molecule oncology therapies, has filed for a Hong Kong IPO.
Deal focus: Australia's ENA hits COVID-19 in the nose
Australian investors see hope in ENA Respiratory, a nasal spray specialist aiming to complement global COVID-19 vaccine programs with an immune system-boosting product
Singapore gene therapy start-up closes $24m Series A
Nuevocor, a preclinical biotech company specializing in gene therapy for heart disease, has closed an oversubscribed Series A round with $24 million in commitments.
China's Nutshell Therapeutics raises $20m
Nutshell Therapeutics, a Chinese drug developer, has raised a $20 million Series A round led by Matrix Partners China.
Chinese pharmaceutical platform Yaoshibang raises $270m
Chinese B2B pharmaceutical trading platform Yaoshibang has raised $270 million from Guangdong Pearl River Investment, Baidu, Sunshine Insurance, Green Pine Capital Partners, Guangzhou government-backed S Fund, and an undisclosed sovereign wealth fund....
TPG leads $220m round for China's Dingdang Health
TPG Capital has led a $220 million round for Chinese online pharmacy services provider Dingdang Health.
China mRNA specialist Stemirna gets $200m in funding
Stemirna Therapeutics, which claims to be the first biotech company to bring an mRNA therapeutics and nanomedicine platform to China, has raised $200 million in funding.
Deal focus: NiKang pursues hard-to-drug targets
With big pharma scaling back early-stage discovery, CBC Group is keen to incubate biotech start-ups developing drugs from scratch. NiKang Therapeutics is the first to secure wider investor attention
Vivo, Novo back Singapore's Esco Lifesciences
Vivo Capital and Novo Holdings have led a $200 million Series A round for Esco Lifesciences, a Singapore-based manufacturer of biopharma lab equipment and medical devices.
Deal focus: Novo spreads its wings in Southeast Asia
In Hummingbird Bioscience and Halodoc, Novo Holdings believes it has backed a potential global leader in hard-to-drug cancer and a likely domestic champion in telemedicine and disease management
Lilly Asia leads $90m round for China's Duality Biologics
Lilly Asia Ventures has led a $90 million Series B round for Duality Biologics, a Chinese developer of oncology and autoimmune drugs.
Singapore biotech start-up closes $125m Series C
Novo Holdings, which manages the wealth of Denmark’s Novo Nordisk Foundation, has led a $125 million Series C round for Hummingbird Bioscience, a Singapore and US-based drug developer.
China GPs commit $160m to local ADC player
DAC Biotech, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised RMB1 billion ($160 million) in Series C funding led by GL Ventures, CDG Capital, and CPE.
China medical tech supplier AMS raises $100m
China and US-based Access Medical Systems (AMS) has raised a $100 million round co-led by Sequoia Capital China and GL Ventures.
China's Hope Medicine raises $56m Series B
Chinese innovative drug company Hope Medicine has raised a $56 million Series B round jointly led by Qiming Venture Partners and Grand Flight Investment.
Chinese COVID-19 vaccine developer Clover files for IPO
Clover Biopharmaceuticals, a Chinese pre-revenue drug developer that has raised $315 million across several funding rounds since 2011, has filed for a Hong Kong IPO.